HistoSonics, the developer of the Edison® Histotripsy System, has announced the enrollment of the first patients in its novel BOOMBOX study, a prospective master protocol designed to assess the real-world application of histotripsy for treating liver tumors. This post-market study…
Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) and Alera Pharma, Inc. today announced the receipt of a second patent allowance for their Conjugated Psilocin™ technology. The patent, titled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof,” covers compositions that…
SOLVD Health, a patient intelligence company focused on precision solutions to improve health outcomes, has launched a comprehensive post-approval study for AvertD®, the first FDA-approved genetic test to assess the risk of opioid use disorder (OUD). The study will build…
Alafia AI, Inc. (“ALAFIA”), a leader in omics computing and precision medicine, is today unveiling an expansion of its high-performance computing (HPC) product line to address the growing demand for scalable, heterogeneous computing in the biopharmaceutical and application development industries.…
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) commended the American College of Rheumatology (ACR) for its newly released 2024 evidence-based guidelines on the screening, treatment, and management of lupus nephritis (LN). The updated guidelines emphasize the urgent need for effective treatments to…
RheaVita, a leader in controlled, continuous freeze-drying technology for biopharmaceuticals, has entered into a strategic partnership with IMA Life, a global leader in advanced aseptic pharmaceutical production solutions and one of the three pharma divisions of IMA Group. The partnership…
At the ISPOR Europe 2024 Conference, CapeStart, Inc. unveiled MadeAi™, a generative AI-powered platform designed to revolutionize the synthesis of clinical information. The platform’s first solution, MadeAi-LR, enhances the efficiency of systematic literature reviews (SLRs), clinical evidence reports (CERs), meta-research,…
BrightHeart, an innovator in AI technology for obstetrics and pediatric cardiology, has received FDA 510(k) clearance for its first AI-driven software, which aims to revolutionize prenatal ultrasound evaluations of the fetal heart. This breakthrough comes at a critical time, as…
Cancer Targeted Technology (CTT), a Seattle-based biotechnology company focused on cancer diagnostics and therapies, announced that the National Cancer Institute has awarded the Phase I portion ($400K) of a fast-track Phase I/II Small Business Innovation Research (SBIR) grant to support…
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial will be presented in…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNA interference (RNAi) therapeutics, today announced positive new results from its ongoing Phase 1 clinical trial of nucresiran (formerly ALN-TTRsc04), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of ATTR…
Oscar Health, Inc. (NYSE: OSCR), a leading healthcare technology company, is expanding its presence in New Jersey by offering a wider range of affordable health insurance plans through the ACA marketplace in 2025. This expansion will make Oscar’s personalized healthcare…